Beneficial effect of atorvastatin on left ventricular remodeling in spontaneously hypertensive rats

Pharmacology

Volumn 80, Issue 2-3, 2007, Pages 120-126

  Kang, Lan ^a   Ge, Chang Jiang ^a   Hu, Shen Jiang ^a,b  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b Shanghai Universities   (China)

Author keywords

Atorvastatin; HMG CoA reductase; Hypertension

Indexed keywords

ATORVASTATIN; COLLAGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BLOOD LEVEL; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; BODY WEIGHT; CONTROLLED STUDY; FIBROSIS; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE HYPERTROPHY; HYPERTENSION; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; STATISTICAL SIGNIFICANCE; SYSTOLIC BLOOD PRESSURE; UPREGULATION;

ANIMALS; APOPTOSIS; BLOOD PRESSURE; CARDIOMEGALY; COLLAGEN; CYCLIN-DEPENDENT KINASE INHIBITOR P27; HEPTANOIC ACIDS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPIDS; MALE; MYOCARDIUM; PYRROLES; RANDOM ALLOCATION; RATS; RATS, INBRED SHR; RATS, INBRED WKY; VENTRICULAR REMODELING;

EID: 34547812121     PISSN: 00317012     EISSN: None     Source Type: Journal    
DOI: 10.1159/000103251     Document Type: Article

References (38)

1. Braunwald E, Zipes DP, Libby P: Heart Disease: A Textbook of Cardiovascular Medicine, ed 6. Philadelphia, Saunders, 2001, pp 503-534.
2. Teiger E, Dam TV, Richard L, et al: Apoptosis in pressure overload-induced heart hypertrophy in the rat. J Clin Invest 1996;97:2891-2897.
3. Sugden PH, Clerk A: Cellular mechanisms of cardiac hypertrophy. J Mol Med 1998;76:725-746.
4. Tea BS, Dam TV, Moreau P, et al: Apoptosis during regression of cardiac hypertrophy in spontaneously hypertensive rats. Temporal regulation and spatial heterogeneity. Hypertension 1999;34:229-235.
5. Buemi M, Corica F, Marino D, et al: Cardiovascular remodeling, apoptosis, and drugs. Am J Hypertens 2000;13:450-454.
6. Lloyd RV, Erickson LA, Jin L, Kulig E, Qian X, Cheville JC: p27KIP1: a multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancers. Am J Pathol 1999;154:312-323.
7. Jing Z, Nan KJ, Hu ML: Cell proliferation, apoptosis and the related regulators p27, p53 expression in hepatocellular carcinoma. World J Gastroenterol 2005;11:1910-1916.
8. Diez-Juan A, Andres V: The growth suppressor p27Kip1 protects against diet-induced atherosclerosis. FASEB J 2001;15:1989-1995.
9. Andres V, Urena J, Poch E, Chen D, Goukassian D: Role of Sp1 in the induction of p27 gene expression in vascular smooth muscle cells in vitro and after balloon angioplasty. Arterioscler Thromb Vasc Biol 2001;21:342-347.
10. Alkarain A, Jordan R, Slingerland JP: p27 deregulation in breast cancer: prognostic significance and implications for therapy. J Mammary Gland Biol Neoplasia 2004;9:67-80.
11. Li JM, Brooks G: Downregulation of cyclin-dependent kinase inhibitors p21 and p27 in pressure-overload hypertrophy. Am J Physiol 1997;273:H1358-H1367.
12. Ginsberg HN: Update on the treatment of hypercholesterolemia, with focus on HMGCoA reductase inhibitor and combination regimes. Clin Cardiol 1995;18:307-315.
13. Son JW, Koh KK, Ahn JY, Jin DK, Park GS, Kim DS, et al: Effects of statin on plaque stability and thrombogenicity in hypercholesterolemic patients with coronary artery disease. Int J Cardiol 2003;88:77-82.
14. Kohno M, Shinomiya K, Abe S, Noma T, Kondo I, Oshita A, et al: Inhibition of migration and proliferation of rat vascular smooth muscle cells by a new HMG-CoA reductase inhibitor, pitavastatin. Hypertens Res 2002;25:279-285.
15. Yasunari K, Maeda K, Minami M, Yoshikawa J: HMG-CoA reductase inhibitors prevent migration of human coronary smooth muscle cells through suppression of increase in oxidative stress. Arterioscler Thromb Vasc Biol 2001;21:937-942.
16. Nicole C, Kaneider Christina M, et al: Induction of apoptosis and inhibition of migration of inflammatory and vascular wall cells by cerivastatin. Atherosclerosis 2001;158:23-33.
17. Guijarro C, Blanco-Colio LM, Massy ZA, et al: Lipophilic statins induce apoptosis of human vascular smooth muscle cells. Kidney Int Suppl 1999;71:S88-S91.
18. Hasegawa H, Yamamoto R, Takano H, et al: 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors prevent the development of cardiac hypertrophy and heart failure in rats. J Mol Cell Cardiol 2003;35:953-960.
19. Nishikawa H, Miura S, Zhang B, et al: Statins induce the regression of left ventricular mass in patients with angina. Circ J 2004;68:121-125.
20. Patel R, Nagueh SF, Tsgbouleva N, et al: Simvastatin induces regression of cardiac hypertrophy and fibrosis and improve cardiac function in a transgenic rabbit model of human hypertrophic cardiomyopathy. Circulation 2001;104:317-324.
21. Wassmann S, Laufs U, Baumer AT, Muller K, Ahlbory K, Linz W, et al: HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species. Hypertension 2001;37:1450-1457.
22. Braun-Dullaeus RC, Mann MJ, Ziegler A, von der Leyen HE, Dzau VJ: A novel role for the cyclin-dependent kinase inhibitor p27(kip1) in angiotensin II-stimulated vascular smooth muscle cell hypertrophy. J Clin Invest 1999;104:815-823.
23. Jung F, Haendeler J, Goebel C, Zeiher AM, Dimmeler S: Growth factor-induced phosphoinositide 3-OH kinase/Akt phosphorylation in smooth muscle cells: induction of cell proliferation and inhibition of cell death. Cardiovasc Res 2000;48:148-157.
24. Tanner FC, Boehm M, Akyurek LM, San H, Yang ZY, Tashiro J, et al: Differential effects of the cyclin-dependent kinase inhibitors p27 (Kip1), p21(cip1), and p16(Ink4) on vascular smooth muscle cell proliferation. Circulation 2000;101:2022-2025.
25. Castro C, Diez-Juan A, Cortes MJ, Andres V: Distinct regulation of mitogen-activated protein kinases and p27Kip1 in smooth muscle cells from different vascular beds. A potential role in establishing regional phenotypic variance. J Biol Chem 2003;278:4482-4490.
26. Soma MR, Donetti E, Parolini C, Mazzini G, Ferrari C, Fumagalli R, et al: HMG CoA reductase inhibitors: in vivo effects on carotid intimal thickening in normocholesterolemic rabbits. Arterioscler Thromb 1993;13:571-578.
27. Herdeg C, Fitzke M, Oberhoff M, Baumbach A, Schroeder S, Karsch KR: Effects of atorvastatin on in-stent stenosis in normo- and hypercholesterolemic rabbits. Int J Cardiol 2003;91:59-69.
28. Muck AO, Seeger H, Wallwiener D: Inhibitory effect of statins on the proliferation of human breast cancer cells. Int J Clin Pharmacol Ther 2004;42:695-700.
29. Graaf MR, Richel DJ, van Noorden CJ, Guchelaar HJ: Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer. Cancer Treat Rev 2004;30:609-641.
30. Yang L, Gao YJ, Lee RM: The effects of quinapril and atorvastatin on artery structure and function in adult spontaneously hypertensive rats. Eur J Pharmacol 2005;518:145-151.
31. Blanco-Colio LM, Villa A, Ortego M, Hernandez-Presa MA, Pascual A, Plaza JJ, et al: 3-Hydroxy-3-methyl-glutaryl coenzyme A reductase inhibitors, atorvastatin and simvastatin, induce apoptosis of vascular smooth muscle cells by downregulation of Bcl-2 expression and Rho A prenylation. Atherosclerosis 2002;161:17-26.
32. Laufs U, Marra D, Node K, Liao JK: 3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors attenuate vascular smooth muscle proliferation by preventing rho GTPase-induced down-regulation of p27(Kip1). J Biol Chem 1999;274:21926-21931.
33. Weiss RH, Ramirez A, Joo A: Short-term pravastatin mediates growth inhibition and apoptosis, independently of Ras, via the signaling proteins p27Kip1 and P13 kinase. J Am Soc Nephrol 1999;10:1880-1890.
34. Wassman S, Faul A, Hennen B: Rapid effect of 3-hydroxy-3-methylglutaryl- CoA reductase inhibition on coronary endothelial function. Circ Res 2003;93:e98-e103.
35. Ling MC, Ruddy TD, Dekemp RA: Early effects of statin therapy on endothelial function and microvascular reactivity in patients with coronary artery disease. Am Heart J 2005;149:1137.
36. Glorioso N, Troffa C, Filigheddu F, et al: Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia. Hypertension 1999;34:1281-1286.
37. Borghi C, Prandin MG, Costa FV, et al: Use of statins and blood pressure control in treated hypertensive patients with hypercholesterolemia. J Cardiovasc Pharmacol 2000;35:549-555.
38. Kanbay M, Yildirir A, Bozbas H, et al: Statin therapy helps to control blood pressure levels in hypertensive dyslipidemic patients. Ren Fail 2005;27:297-303.